Rachel Lutz

Traumatic life events are often associated with attention-deficit/hyperactivity disorder, according to research presented at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.

The development of epilepsy and subsequent seizures was prevented in animal models following the use of losartan, a common hypertension drug.

Although they are revolutionary for the treatment of various gastric acid-related disorders, proton pump inhibitors may be linked to interstitial nephritis, according to research published in Kidney International.

The FDA's Cardiovascular and Renal Drugs Advisory Committee convenes today to discuss serelaxin after reviewers recommended against the approval of the heart failure drug.

Empathy is not an explanation for contagious yawning, according to a study published in PLOS ONE.

A once-weekly self-injection pen has been approved by the FDA to supplement diet and exercise for type 2 diabetes patients.

Infants with autism who were fed soy-based formula had more seizures than their counterparts fed dairy-based formulas, according to a study published in PLOS ONE.

Reading and language skills development are slowed by high levels of metabolites glutamate and choline in the brain, according to a study published in the

Atypical development in younger siblings of children with autism spectrum disorder can be detected as early as 12 months old.

Aveed (testosterone undecanoate), an injection drug designed to combat hypogonadism, has been approved by the FDA after being rejected 3 times.

Scientists have identified and blocked the trigger for autism and other mental illnesses in stem cells that test positive for fragile X syndrome.

A minimally-invasive, surgically-implanted esophagus band developed at Stony Brook University Hospital effectively reduces symptoms of gastroesophageal reflux disease (GERD).

Results from a small study show that adding donepezil may provide additional analgesic relief for neuropathic pain patients who do not receive sufficient pain relief from gabapentin.

A Federal Drug Administration advisory panel of experts has recommended that Merck's antiplatelet drug vorapaxar be approved for use as add-on therapy in patients with a history of heart attack.

Results from animal models of depression and a human clinical trial show that enhancing, instead of blocking, the NMDA glutamate receptor can cause antidepressant-like effects.